Tasrina Rahman

Tasrina Rahman

Auto-generated profile, based on publicly available information

Tasrina Rahman

Division of Hematology and Oncology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 1

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2021 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
BKBassem D. Khalil
Bassem D. Khalil
RSRoberto Sanchez
Roberto Sanchez
TRTasrina Rahman
Tasrina Rahman
CRCarolina A Rodriguez-Tirado
Carolina A Rodriguez-Tirado
SMStefan Moritsch
Stefan Moritsch
JAJulio A. Aguirre-Ghiso
Julio A. Aguirre-Ghiso
We describe the discovery of an agonist of the nuclear receptor NR2F1 that specifically activates dormancy programs in malignant cells. The agonist led to a self-regulated increase in NR2F1 mRNA and protein and downstream transcription of a novel dormancy program. This program led to growth arrest of an HNSCC PDX line, human cell lines, and patient-derived organoids in 3D cultures and in vivo. This effect was lost when NR2F1 was knocked out by CRISPR-Cas9. RNA sequencing revealed that agonist treatment induces transcriptional changes associated with inhibition of cell cycle progression and mTOR signaling, metastasis suppression, and induction of a neural crest lineage program. In mice, agonist treatment resulted in inhibition of lung HNSCC metastasis, even after cessation of the treatment, where disseminated tumor cells displayed an NR2F1hi/p27hi/Ki-67lo/p-S6lo phenotype and remained in a dormant single-cell state. Our work provides proof of principle supporting the use of NR2F1 agonists to induce dormancy as a therapeutic strategy to prevent metastasis.